Comparison studies of cholinesterase inhibitors for Alzheimer's disease

Lancet Neurology
David B HoganChristopher Patterson

Abstract

There is uncertainty about which of the three available cholinesterase inhibitors should be prescribed as initial therapy for patients with Alzheimer's disease. We have assessed the reports of three trials that directly compared cholinesterase inhibitors. They were reviewed for sponsorship, authorship, main results, proportions of individuals who achieved maximum daily doses of the study cholinesterase inhibitors, and how the studies dealt with items on the CONSORT checklist for randomised controlled trials. All studies were funded by pharmaceutical companies, coauthored by their employees, and reported results that favoured the sponsor's product. In two studies, a significantly lower proportion of people achieved the target maximum daily dose for the comparator drug than for the sponsor's product. Between 27% and 55% of CONSORT items per study were rated as inadequately reported. The methodological limitations of these studies reduce our confidence in the validity of the conclusions drawn in the published reports.

References

Jun 1, 1991·Journal of Clinical Pharmacology·B Spilker
Aug 27, 1999·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·C R Reed, C A Camargo
Sep 1, 2000·Lancet·B DjulbegovicG H Lyman
Apr 17, 2001·Annals of Internal Medicine·D G AltmanUNKNOWN CONSORT GROUP (Consolidated Standards of Reporting Trials)
Aug 15, 2001·Neurology·B WinbladUNKNOWN Donepezil Nordic Study Group
Sep 28, 2001·Journal of the American Podiatric Medical Association·D MoherUNKNOWN CONSORT Group (Consolidated Standards of Reporting Trials)
Jul 24, 2003·Drugs & Aging·Gordon WilcockUNKNOWN GAL-GBR-2 Study Group

❮ Previous
Next ❯

Citations

Dec 15, 2007·Molecular Diagnosis & Therapy·Ramón Cacabelos
Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Ramón Cacabelos
Jun 10, 2010·International Journal of Clinical Practice·J LindesayT van Laar
May 25, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Nicolas WanaverbecqDimitri M Kullmann
Oct 19, 2010·Evidence-based Complementary and Alternative Medicine : ECAM·Richard HammerschlagMikel Aickin
May 2, 2007·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·David B Hogan
Oct 4, 2005·Expert Opinion on Pharmacotherapy·Ramón Cacabelos
Aug 9, 2005·Current Medical Research and Opinion·Roger BullockRoger Lane
May 6, 2015·Drugs & Aging·Jacob S Buckley, Shelley R Salpeter
Sep 16, 2005·Expert Review of Neurotherapeutics·Abhilash K Desai, George T Grossberg
Apr 16, 2010·American Journal of Alzheimer's Disease and Other Dementias·Frederick A SchmittJason T Olin
May 7, 2008·Expert Review of Neurotherapeutics·Paul R Solomon, Cynthia A Murphy
Aug 10, 2013·Expert Review of Clinical Pharmacology·Gabriel C Léger, Fadi Massoud
Feb 24, 2015·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Colleen J MaxwellNathan Herrmann
Oct 1, 2007·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·David B HoganLilian Thorpe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.